U.S. markets closed
  • S&P Futures

    4,026.50
    +16.50 (+0.41%)
     
  • Dow Futures

    33,246.00
    +209.00 (+0.63%)
     
  • Nasdaq Futures

    13,322.75
    +6.75 (+0.05%)
     
  • Russell 2000 Futures

    2,283.00
    +31.10 (+1.38%)
     
  • Crude Oil

    61.07
    -0.38 (-0.62%)
     
  • Gold

    1,726.10
    -2.30 (-0.13%)
     
  • Silver

    24.97
    +0.02 (+0.09%)
     
  • EUR/USD

    1.1770
    +0.0001 (+0.01%)
     
  • 10-Yr Bond

    1.6790
    -0.0670 (-3.84%)
     
  • Vix

    17.33
    -2.07 (-10.67%)
     
  • GBP/USD

    1.3835
    +0.0006 (+0.04%)
     
  • USD/JPY

    110.5660
    -0.0920 (-0.08%)
     
  • BTC-USD

    58,352.74
    +664.36 (+1.15%)
     
  • CMC Crypto 200

    1,214.96
    +11.79 (+0.98%)
     
  • FTSE 100

    6,737.30
    +23.67 (+0.35%)
     
  • Nikkei 225

    30,083.19
    +229.19 (+0.77%)
     

SHAREHOLDER ALERT: BLUE HSACW APA: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines

  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
·3 min read
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.

NEW YORK, NY / ACCESSWIRE / April 4, 2021 / The Law Offices of Vincent Wong announce that class actions have commenced on behalf of certain shareholders in the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff. There will be no obligation or cost to you.

bluebird bio, Inc. (NASDAQ:BLUE)

If you suffered a loss, contact us at:http://www.wongesq.com/pslra-1/bluebird-bio-inc-loss-submission-form?prid=14344&wire=1
Lead Plaintiff Deadline: April 13, 2021
Class Period: May 11, 2020 - November 4, 2020

Allegations against BLUE include that: (i) data supporting bluebird's BLA submission for LentiGlobin for SCD was insufficient to demonstrate drug product comparability; (ii) Defendants downplayed the foreseeable impact of disruptions related to the COVID-19 pandemic on the Company's BLA submission schedule for LentiGlobin for SCD, particularly with respect to manufacturing; (iii) as a result of all the foregoing, it was foreseeable that the Company would not submit the BLA for LentiGlobin for SCD in the second half of 2021; and (iv) as a result, the Company's public statements were materially false and misleading at all relevant times.

Immunovant, Inc. f/k/a Health Sciences Acquisitions Corporation (NASDAQ:HSACW)

If you suffered a loss, contact us at:http://www.wongesq.com/pslra-1/immunovant-inc-f-k-a-health-sciences-acquisitions-corporation-loss-submission-form?prid=14344&wire=1
Lead Plaintiff Deadline: April 20, 2021
Class Period: October 2, 2019 - February 1, 2021

Allegations against HSACW include that: (i) HSAC had performed inadequate due diligence into Legacy Immunovant prior to the Merger, and/or ignored or failed to disclose safety issues associated with IMVT-1401; (ii) IMVT-1401 was less safe than the Company had led investors to believe, particularly with respect to treating TED and WAIHA; (iii) the foregoing foreseeably diminished IMVT-1401's prospects for regulatory approval, commercial viability, and profitability; and (iv) as a result, the Company's public statements were materially false and misleading at all relevant times.

Apache Corporation (NASDAQ:APA)

If you suffered a loss, contact us at:http://www.wongesq.com/pslra-1/apache-corporation-loss-submission-form?prid=14344&wire=1
Lead Plaintiff Deadline: April 26, 2021
Class Period: September 7, 2016 - March 13, 2020

Allegations against APA include that: (i) Apache intentionally used unrealistic assumptions regarding the amount and composition of available oil and gas in Alpine High; (ii) Apache did not have the proper infrastructure in place to safely and/or economically drill and/or transport those resources even if they existed in the amounts purported; (iii) these misleading statements and omissions artificially inflated the value of the Company's operations in the Permian Basin; and (iv) as a result, the Company's public statements were materially false and misleading at all relevant times.

To learn more contact Vincent Wong, Esq. either via email vw@wongesq.com or by telephone at 212.425.1140.

Vincent Wong, Esq. is an experienced attorney who has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
Vincent Wong, Esq.
39 East Broadway
Suite 304
New York, NY 10002
Tel. 212.425.1140
Fax. 866.699.3880
E-Mail: vw@wongesq.com

SOURCE: The Law Offices of Vincent Wong



View source version on accesswire.com:
https://www.accesswire.com/638903/SHAREHOLDER-ALERT-BLUE-HSACW-APA-The-Law-Offices-of-Vincent-Wong-Reminds-Investors-of-Important-Class-Action-Deadlines